Germ cell tumors: An update of recent data and review of active protocols in stage I and metastatic disease

Noah Hahn, Christopher J. Sweeney

Research output: Contribution to journalArticle

Abstract

Germ cell tumors are highly curable malignancies even when metastatic. Investigations currently focus on curtailing toxicity in low-risk patients and improving cure rates in poor-risk individuals. Reduced dose radiation schedules and short-course chemotherapy regimens have been evaluated in stage I disease. In metastatic disease, several new nonplatinum agents offer promise for patients with poor risk or relapsed disease. In addition, high-dose chemotherapy regimens with autologous stem cell transplant provide potential for further improvements in survival. This review will highlight recent developments and currently active clinical trials pertinent to the treatment of patients with germ cell tumors.

Original languageEnglish (US)
Pages (from-to)293-302
Number of pages10
JournalUrologic Oncology: Seminars and Original Investigations
Volume23
Issue number4
DOIs
StatePublished - Jul 2005
Externally publishedYes

Fingerprint

Germ Cell and Embryonal Neoplasms
Drug Therapy
Appointments and Schedules
Stem Cells
Clinical Trials
Radiation
Transplants
Survival
Neoplasms
Therapeutics

Keywords

  • Clinical trials
  • Evidence
  • Germ cell tumor
  • Metastases
  • Nonseminoma
  • Seminoma
  • Stage I
  • Update

ASJC Scopus subject areas

  • Oncology
  • Urology

Cite this

Germ cell tumors : An update of recent data and review of active protocols in stage I and metastatic disease. / Hahn, Noah; Sweeney, Christopher J.

In: Urologic Oncology: Seminars and Original Investigations, Vol. 23, No. 4, 07.2005, p. 293-302.

Research output: Contribution to journalArticle

@article{88ce35407af34c98bbc92d467e41f392,
title = "Germ cell tumors: An update of recent data and review of active protocols in stage I and metastatic disease",
abstract = "Germ cell tumors are highly curable malignancies even when metastatic. Investigations currently focus on curtailing toxicity in low-risk patients and improving cure rates in poor-risk individuals. Reduced dose radiation schedules and short-course chemotherapy regimens have been evaluated in stage I disease. In metastatic disease, several new nonplatinum agents offer promise for patients with poor risk or relapsed disease. In addition, high-dose chemotherapy regimens with autologous stem cell transplant provide potential for further improvements in survival. This review will highlight recent developments and currently active clinical trials pertinent to the treatment of patients with germ cell tumors.",
keywords = "Clinical trials, Evidence, Germ cell tumor, Metastases, Nonseminoma, Seminoma, Stage I, Update",
author = "Noah Hahn and Sweeney, {Christopher J.}",
year = "2005",
month = "7",
doi = "10.1016/j.urolonc.2005.05.008",
language = "English (US)",
volume = "23",
pages = "293--302",
journal = "Urologic Oncology",
issn = "1078-1439",
publisher = "Elsevier Inc.",
number = "4",

}

TY - JOUR

T1 - Germ cell tumors

T2 - An update of recent data and review of active protocols in stage I and metastatic disease

AU - Hahn, Noah

AU - Sweeney, Christopher J.

PY - 2005/7

Y1 - 2005/7

N2 - Germ cell tumors are highly curable malignancies even when metastatic. Investigations currently focus on curtailing toxicity in low-risk patients and improving cure rates in poor-risk individuals. Reduced dose radiation schedules and short-course chemotherapy regimens have been evaluated in stage I disease. In metastatic disease, several new nonplatinum agents offer promise for patients with poor risk or relapsed disease. In addition, high-dose chemotherapy regimens with autologous stem cell transplant provide potential for further improvements in survival. This review will highlight recent developments and currently active clinical trials pertinent to the treatment of patients with germ cell tumors.

AB - Germ cell tumors are highly curable malignancies even when metastatic. Investigations currently focus on curtailing toxicity in low-risk patients and improving cure rates in poor-risk individuals. Reduced dose radiation schedules and short-course chemotherapy regimens have been evaluated in stage I disease. In metastatic disease, several new nonplatinum agents offer promise for patients with poor risk or relapsed disease. In addition, high-dose chemotherapy regimens with autologous stem cell transplant provide potential for further improvements in survival. This review will highlight recent developments and currently active clinical trials pertinent to the treatment of patients with germ cell tumors.

KW - Clinical trials

KW - Evidence

KW - Germ cell tumor

KW - Metastases

KW - Nonseminoma

KW - Seminoma

KW - Stage I

KW - Update

UR - http://www.scopus.com/inward/record.url?scp=21844446838&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=21844446838&partnerID=8YFLogxK

U2 - 10.1016/j.urolonc.2005.05.008

DO - 10.1016/j.urolonc.2005.05.008

M3 - Article

C2 - 16018947

AN - SCOPUS:21844446838

VL - 23

SP - 293

EP - 302

JO - Urologic Oncology

JF - Urologic Oncology

SN - 1078-1439

IS - 4

ER -